The transgenic HIV-1 rat (Tg) is a commonly used neuroHIV model with documented neurologic/behavioral deficits. Using immunofluorescent staining of the Tg brain, we found astrocytic dysfunction/damage, as well as dopaminergic neuronal loss/dysfunction, both of which worsening significantly in the striatum with age. We saw mild microglial activation in young Tg brains, but this decreased with age. There were no differences in neurogenesis potential suggesting a neurodegenerative rather than a neurodevelopmental process. Gp120 CSF levels exceeded serum gp120 levels in some animals, suggesting local viral protein production in the brain. Further probing of the pathophysiology underlying astrocytic injury in this model is warranted.
Introduction
Since the introduction of anti-retroviral therapy (ART), the prevalence of HIV-associated dementia (HAD) decreased, however less fulminant forms of HIV-related neurological dysfunction became more common and currently affect around 52% of the HIV-positive (HIV+) patient population (McArthur et al., 2003 (McArthur et al., , 2010 . The exact neuropathology leading to milder forms of HIV-associated neurocognitive disorders (HAND) is not fully understood but is probably multifactorial. Unlike microglia and astrocytes, neurons do not seem to get productively infected with HIV (Kovalevich and Langford, 2012) . The neurologic damage is rather thought related to persistent low level neuroinflammation (Desplats et al., 2013) , neurotoxic effects of viral proteins (Agrawal et al., 2012; Hu et al., 2009; Mocchetti et al., 2011) , as well as the disruption of the supportive and neurotrophic role of astrocytes (Bezzi et al., 2001 ) and oligodendrocytes (Radja et al., 2003) .
Short of using expensive and sentient SIV infected monkeys, or sophisticated humanized mice models, the HIV-1 transgenic (Tg) rat is used by many groups as an HIV model. This non-infectious rat model expresses 7 of the 9 HIV-1 viral proteins including gp120, nef and tat and is known to develop clinically relevant neuropathologies (Reid et al., 2001 ) and cognitive deficits (Lashomb et al., 2009; Moran et al., 2012 Moran et al., , 2013a Peng et al., 2010; Vigorito et al., 2007) . It thus appears to be of particular importance and practicality for the evaluation of neurological HIV complications.
In this study, we wanted to better understand the pattern of neurotoxicity underlying the neurological and behavioral problems described in the commercially-available Tg rat. Towards this goal, we compared immunofluorescence staining of various neuronal and glial markers, dopaminergic function and neurogenesis potential between the Tg and WT rats, at different ages. We also measured the levels of gp120 (as a representative viral protein) in the cerebrospinal fluid (CSF) and compared to serum levels of.
